NASDAQ:ZSQR Coeptis Therapeutics Q4 2025 Earnings Results & Report $5.16 -0.34 (-6.18%) As of 04:00 PM Eastern Coeptis Therapeutics reported Q4 2025 earnings on March 19, 2026. The company reported EPS of -$0.12, while revenue was $0.86 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 19, 2026TimeAfter Market Closes Coeptis Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACoeptis Therapeutics Revenue ResultsActual Revenue$0.86 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Coeptis Therapeutics Q4 2025 Earnings FAQ Did Coeptis Therapeutics beat earnings estimates for Q4 2025? Coeptis Therapeutics (NASDAQ:ZSQR) reported earnings of -$0.12 per share for Q4 2025. The report was announced on Thursday, March 19, 2026. What was Coeptis Therapeutics' revenue for Q4 2025? Coeptis Therapeutics reported revenue of $0.86 million for Q4 2025. Coeptis Therapeutics Earnings HeadlinesZ Squared Inc. CEO David Halabu Discusses AI Data Center Strategy on Two Investor PodcastsSeptember 18, 2026 | prnewswire.comZ Squared Acquires Energized Arkansas Campus to Advance AI Infrastructure StrategySeptember 9, 2026 | prnewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 13 at 1:00 AM | Porter & Company (Ad)Z Squared CEO to Shareholders: "The Scarcest Thing in AI is Not Chips. It is Power.August 14, 2026 | prnewswire.comZ Squared Inc. Signs Definitive Agreement to Acquire 100% of Paradox Data and Its Union County CampusAugust 3, 2026 | prnewswire.comZ Squared Inc. Terminates At-The-Market Sales Agreement and Committed Equity Forward Purchase AgreementJuly 17, 2026 | prnewswire.comSee More Coeptis Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coeptis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coeptis Therapeutics and other key companies, straight to your email. Email Address About Coeptis TherapeuticsCoeptis Therapeutics (NASDAQ:ZSQR) is a biotechnology company focused on developing cell therapy platforms and other treatments for cancer and autoimmune diseases. The company’s research is centered on approaches intended to improve the targeting, flexibility and potential effectiveness of immune-cell therapies. Its principal platform, SNAP-CAR, is designed to support adaptable chimeric antigen receptor (CAR) cell therapies that can target different disease-associated antigens. Coeptis has also pursued related therapeutic programs through collaborations and licensing arrangements, including research involving natural killer (NK) cells and other immune-based treatment technologies. Coeptis is based in the United States and has focused primarily on developing its pipeline through strategic partnerships and biotechnology collaborations. The company’s programs remain investigational and are subject to preclinical and clinical development requirements before any potential commercialization.View Coeptis Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
